Liquidia’s LIQ-001is a seasonal influenza vaccine for protection in the elderly and represents the company’s migration from proof of concept to the clinical application of PRINT technology.
Liquidia chief medical officer Frank Malinoski said that the primary objective of this trial is to evaluate the safety and immune response in healthy young adults and adults over 65, a group that often responds sub-optimally to standard flu vaccines.
“We believe that this vaccine, using proprietary PRINT particles, has the potential to offer immune response and an improved safety and tolerability profile as compared to alternative approaches to delivering the influenza vaccine,” Malinoski said.
Liquidia CEO Neal Fowler said that advancing first vaccine product from concept, through GMP production, to a clinical candidate in just over 18 months demonstrates the power and simplicity of the vaccines technology platform here at Liquidia.
“We believe our particle engineering and manufacturing control are unprecedented and provide us with a unique opportunity to improve the prevention and treatment of diseases for patients worldwide.”